After Hours news: PT (NASDAQ: PTIX), today announced its profitability for the fourth quarter 2011. Highlights: Working capital position in the fourth quarter 2011 was $18.3 million including cash and investments amounting to $15.8 million Company had no long-term debt as the end of the fourth quarter 2011 Revenue in the fourth quarter 2011 amounted […]
Home» Posts tagged "NuPathe"
30% Gains in Day-trading with NuPathe Inc. (NASDAQ: PATH)
NuPathe Inc. (NASDAQ: PATH) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) regarding the New Drug Application (NDA) for its migraine patch (Zelrix). PATH shares plunged to $2.06 at pre-market trading hours. PATH traded over 5.7M shares compared to 204K 10day average volume. Our […]